ITA6555
ITA6555
ITA6555
from
$526.00
Price in reward points: 526
- Catalog: ITA6555
- Gene/Protein: HLA-DRA
- Product Description: Immunotag™ HLA-DRA Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein HLA-DRA Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide derived from human HLA-DRA Specificity HLA-DRA Antibody detects endogenous levels of total HLA-DRA Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name HLA-DRA Accession No. P01903 Alternate Names CD; CELIAC 1; CELIAC1; DP beta 1 chain; DP(W4) beta chain; DPB1; DPB1_HUMAN; DQ A1; DRB1; DRB4; FLJ27088; FLJ27328; GSE; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DR 1 beta; HLA class II histocompatibility antigen DR alpha; HLA class II histocompatibility antigen DR alpha chain; HLA DP histocompatibility type beta 1 subunit; HLA DP1B; HLA DPB1; HLA DQA; HLA DQA1; HLA DQB; HLA DQB1; HLA DR1B; HLA DR3B; HLA DR4B; HLA DRA; HLA DRA1; HLA DRB1; HLA DRB3; HLA DRB4; HLA DRB5; HLA-DPB1; IDDM 1; IDDM1; Major histocompatibility complex class II DP beta 1; Major histocompatibility complex class II DQ alpha 1; Major histocompatibility complex class II DQ beta 1; Major histocompatibility complex class II DR alpha; Major histocompatibility complex class II DR beta 1; Major histocompatibility complex class II DR beta 3; Major histocompatibility complex class II DR beta 4; Major histocompatibility complex class II DR beta 5; MGC117330; MHC class II antigen DPB1; MHC class II antigen DRA; MHC class II HLA DQ alpha 1; MHC class II HLA DR beta 1; MHC class II HLA DR beta 3; MHC DPB1; MHC DQ beta; MHC HLA DPB1; MHC HLA DQ alpha; Description Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 29kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | HLA-DRA |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human HLA-DRA |
| Specificity | HLA-DRA Antibody detects endogenous levels of total HLA-DRA |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | HLA-DRA |
| Accession No. | P01903 |
| Alternate Names | CD; CELIAC 1; CELIAC1; DP beta 1 chain; DP(W4) beta chain; DPB1; DPB1_HUMAN; DQ A1; DRB1; DRB4; FLJ27088; FLJ27328; GSE; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DR 1 beta; HLA class II histocompatibility antigen DR alpha; HLA class II histocompatibility antigen DR alpha chain; HLA DP histocompatibility type beta 1 subunit; HLA DP1B; HLA DPB1; HLA DQA; HLA DQA1; HLA DQB; HLA DQB1; HLA DR1B; HLA DR3B; HLA DR4B; HLA DRA; HLA DRA1; HLA DRB1; HLA DRB3; HLA DRB4; HLA DRB5; HLA-DPB1; IDDM 1; IDDM1; Major histocompatibility complex class II DP beta 1; Major histocompatibility complex class II DQ alpha 1; Major histocompatibility complex class II DQ beta 1; Major histocompatibility complex class II DR alpha; Major histocompatibility complex class II DR beta 1; Major histocompatibility complex class II DR beta 3; Major histocompatibility complex class II DR beta 4; Major histocompatibility complex class II DR beta 5; MGC117330; MHC class II antigen DPB1; MHC class II antigen DRA; MHC class II HLA DQ alpha 1; MHC class II HLA DR beta 1; MHC class II HLA DR beta 3; MHC DPB1; MHC DQ beta; MHC HLA DPB1; MHC HLA DQ alpha; |
| Description | Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 29kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |